Clinical Trials Directory

Trials / Unknown

UnknownNCT05815394

177Lu-labeled NY108 SPECT Imaging in Patients

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Affiliated Hospital of Jiangnan University · Academic / Other
Sex
Male
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled NY108 (177Lu-NY108) SPECT Imaging in patients.

Conditions

Interventions

TypeNameDescription
DRUG177Lu-labeled NY108Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.

Timeline

Start date
2023-03-03
Primary completion
2024-03-03
Completion
2024-12-12
First posted
2023-04-18
Last updated
2023-04-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05815394. Inclusion in this directory is not an endorsement.

177Lu-labeled NY108 SPECT Imaging in Patients (NCT05815394) · Clinical Trials Directory